Introduction
============

Bone is the most common site of breast cancer metastasis, and bone metastases are present in 65% to 75% of patients with metastatic breast cancer [@B1]-[@B4]. Moreover, bone has been reported to be the most common site of first distant relapse of breast cancer [@B5], [@B6]. Bone metastases of breast cancer are generally incurable, but survival times are longer when sites of metastasis are limited to bone than when breast cancer has metastasized to other sites. Bone metastasis of breast cancer can cause skeletal-related events such as bone pain, hypercalcemia, pathologic fracture, and compression of the spinal cord, all of which decrease quality of life [@B7], and skeletal-related events are strongly associated with mortality among breast cancer patients [@B8].

Clinical management of bone metastasis from breast cancer is challenging. Palliative radiation therapy has been used for relief of bone pain and prevention of skeletal-related events in patients with bone metastasis [@B9]. Bone-targeted therapies such as zoledronic acid and denosumab, a monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (RANK-L), have been the standard drugs used to manage bone metastasis and reduce the frequency of skeletal-related events associated with poor quality of life [@B10]. Recently, radium-223 dichloride alpha-particle (radium-223) therapy, which was approved for symptomatic bone metastasis from castration-resistant prostate cancer [@B11], increased survival in a breast cancer mouse model of bone metastasis [@B12]. This promising treatment was tolerated in patients with bone disease who experienced disease progression during endocrine therapy in a phase IIa study [@B13]. Phase II studies of radium-223 in breast cancer patients with bone metastasis are ongoing (NCT02258464, NCT02258451, NCT02366130). However, no drugs have been identified that target bone metastasis and extend survival in breast cancer patients with bone metastasis.

Identification of somatic mutations and clinicopathological characteristics that are more prevalent in patients with bone-only first metastasis than in patients with first metastasis in non-bone sites only ("other-only first metastasis") could identify novel targets for treatment and prevention of bone metastasis from breast cancer. However, whether specific mutations are associated with breast cancer metastasis to bone only as the first site of metastasis is poorly understood. Thus, we compared and contrasted somatic hotspot mutations, clinicopathologic characteristics, and survival in patients with untreated primary breast cancer with bone-only versus other-only first metastasis.

Methods
=======

Patient Selection
-----------------

Patients included in the study were drawn from a larger group of patients whose tumor samples were examined for gene mutations at The University of Texas MD Anderson Cancer Center during the period from March 2012 through December 2014 as part of Institutional Review Board-approved protocol PA11-0852. All patients provided informed consent before enrollment in PA11-0852. Inclusion criteria for PA11-0852 were a diagnosis of cancer, an available tumor sample previously collected from either a primary tumor or a metastasis, and potential to benefit from somatic genomic testing. To be eligible for the study reported herein, patients had to have breast cancer with distant metastasis identified at the time of diagnosis of the primary tumor. They also had to have a primary breast tumor sample collected before treatment to avoid any influence of treatment on mutations; treatment has previously been reported to induce *TP53* and *PIK3CA* mutations [@B14]. Finally, patients had to have information available about the first site of metastasis.

We identified 922 patients with distant metastasis at diagnosis of breast cancer who had samples obtained before treatment and submitted for molecular testing in PA11-0852 during the study period. Of these 922 patients, 482 patients had specimens obtained from a metastasis and were excluded; 440 had specimens obtained from the primary tumor. From these 440 patients, we excluded the 51 patients for whom no information was available about the site of first metastasis, leaving 389 patients in this study.

Tumor Sample Analysis
---------------------

Specimens included formalin-fixed, paraffin-embedded core needle biopsy specimens and tumor resection specimens. Tumor-rich areas were manually macrodissected, and only cases with more than 20% tumor cellularity were included. Tumors were classified as grade 1 (low grade), grade 2 (intermediate grade), or grade 3 (high grade) according to the Nottingham grading system, which is based on a combination of nuclear grade, tubule formation, and mitotic rate. Tumors were defined as hormone receptor positive if immunohistochemical (IHC) staining of archival tumor tissue samples for estrogen receptor (antibody clone 6F11-Novacastra) or progesterone receptor (antibody clone PgR1294-DAKO) showed expression in at least 10% of cells [@B15]. HER2-positive status was defined as 3+ IHC staining or a HER2/CEP17 ratio ≥ 2.0 on fluorescence in situ hybridization [@B16]. All histologic diagnoses and grading and IHC staining results were reviewed by the breast pathology service at MD Anderson Cancer Center.

Genomic Analysis
----------------

In each sample, 46 or 50 commonly mutated cancer-related genes were selectively analyzed for mutations by AmpliSeq Ion Torrent next-generation sequencing as previously described [@B17], [@B18]. This is a multiplex PCR-based library preparation method by which 190 regions (70-150 bp) that encompass 740 mutational hotspots in the coding sequence of 46 or 50 cancer-related genes are analyzed for mutations using multiple markers of detection [@B17]. The following genes were included in the 46-gene panel: *ABL1*, *AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNAS, HNF1A, HRAS, IDH1, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53*, and *VHL* [@B19]. The 50-gene panel included those 46 genes plus *EZH2, GNA11, GNAQ*, and *IDH2*.

Statistical Analysis
--------------------

Overall survival (OS) was measured from the date of diagnosis of primary breast cancer to the date of death or last follow-up. OS was calculated by using Kaplan-Meier estimators, and the log-rank test was used to compare the Kaplan-Meier curves. Continuous variables were evaluated by using the Cox proportional hazards model. Rates of somatic mutations were compared between patient groups by using Fisher\'s exact test. The associations between bone metastasis and clinicopathological variables of interest were evaluated; these variables included age at diagnosis, race, sex, menopausal status at diagnosis, histology, grade, and subtype (hormone receptor positive or negative, HER2 positive or negative, and triple-negative or not). The association between mutation status and clinicopathologic variables of interest was estimated by using logistic regression models. Variables statistically significant (*p* \< 0.05) in univariate analysis and site of first metastasis were selected for multivariate analysis.

Results
=======

Patient Characteristics
-----------------------

Patient demographic and clinical characteristics by site of first metastasis are shown in Table [1](#T1){ref-type="table"}. Among the 389 patients in the study, 72 (18.5%) had bone-only first metastasis, 223 (57.3%) had other-only first metastasis, and 94 (24.2%) had first metastasis in both bone and non-bone sites. Compared to patients with other-only first metastasis, patients with bone-only first metastasis had higher rates of lower grade (grade 1 and 2) (*p*\<0.001), hormone-receptor-positive disease (*p*\<0.001), and non-triple-negative subtype (*p*\<0.001) and a lower ratio of cases of invasive ductal carcinoma to cases of invasive lobular carcinoma (*p*=0.002). Rates of HER2 positivity did not differ between patients with bone-only and other-only first metastasis (*p*=0.10).

Overall Survival
----------------

OS for the entire study group and by site of metastasis and mutation status is shown in Table [2](#T2){ref-type="table"}. The median OS in patients with bone-only first metastasis was 126 months, and the median OS in patients with other-only first metastasis was 85 months. The 5-year OS rate tended to be higher for patients with bone-only first metastasis than for patients with other-only first metastasis (78.2% vs 55.0%; *p*=0.051). However, in the subgroup of patients with *TP53* mutation and in the subgroup of patients with *PIK3CA* mutation, OS did not differ between patients with bone-only and other-only first metastasis (*p*=0.49 and *p*=0.68; respectively). The numbers of patients with *AKT1* and *PTEN* mutations were too small to permit subgroup analysis of differences in OS between patients with bone-only and other-only first metastasis among patients with these mutations.

Mutation Analysis
-----------------

Somatic mutations in four genes, *TP53*, *PIK3CA*, *AKT*, and *PTEN*, were detected among the 389 patients. Mutation rates for the overall study group and subgroups defined by site of first metastasis are shown in Table [3](#T3){ref-type="table"}. In the overall study group (389 patients), *TP53* mutations were the most common, detected in 103 patients (26.5%); *PIK3CA* mutations were detected in 79 patients (20.3%), *AKT* mutations were detected in 13 patients (3.3%), and *PTEN* mutations were detected in two patients (0.5%). In the 72 patients with bone-only first metastasis, *PIK3CA* mutations were the most common, detected in 18 patients (25.0%); *TP53* mutations were detected in 11 patients (15.3%) and *AKT* mutations were detected in two patients (2.8%). In univariate analysis, the rate of *TP53* mutation tended to be lower in patients with bone-only first metastasis than in those with other-only first metastasis (15.3% vs 29.1%; *p*=0.051), but the rates of *PIK3CA*, *AKT*, and *PTEN* mutations were not significantly different between patients with bone-only and other-only first metastasis. In multivariate logistic regression analysis, *TP53* mutation was not significantly associated with site of first metastasis (*p*=0.54) but was significantly associated with hormone-receptor-negative disease (*p*\<0.001) (Table [4](#T4){ref-type="table"}).

Discussion
==========

Mutational profiles have revealed mutations whose frequency differs between primary and metastatic breast cancer. These mutations might be targeted therapeutically and might be associated with resistance to existing therapies in metastatic breast cancer. For example, *PIK3CA* mutation status, which is related to the PI3K/Akt/mTOR signaling pathway, showed discordance between primary and metastatic breast cancer [@B20], and *ESR1* and *RB1* mutations were detected in metastatic breast cancer but infrequently mutated in primary breast cancer [@B21]. Furthermore, several studies have demonstrated that signaling pathways and somatic mutations are associated with bone metastasis in breast cancer, and these pathways and mutations may be rational targets for treatment and prevention of bone metastasis. For example, a gene-expression signature of c-Src activation is associated with bone metastasis in breast cancer, and activation of the Src signaling pathway increases the predilection of a subset of primary breast cancer cells to metastasize to bone [@B22]. Runt-related transcription factor 2 (RUNX2) significantly contributes to bone metastasis in breast cancer [@B23]-[@B25]. *SNAI2* is activated by ERα signaling and promoted bone metastasis [@B26], while*SNAI2* is negatively correlated with ERα signaling and suppressed non-bone metastasis in breast cancer [@B22], [@B26], [@B27].

In our current study, we did not find associations between somatic mutations and bone-only first metastasis in patients with untreated breast cancer. We did confirm previous analyses showing that compared to first metastasis to non-bone site, first metastasis to bone was associated with well-differentiated tumors, hormone-receptor-positive disease, and a lower ratio of cases of invasive ductal carcinoma to cases of invasive lobular carcinoma, all of which are known favorable tumor factors [@B6], [@B28]-[@B32]. Although OS of patients with bone-only first metastasis tended to be longer than that of patients with other-only first metastasis, OS did not differ between patients with bone-only and other-only first metastasis in the subgroup of patients with *TP53* mutation or in the subgroup of patients with *PIK3CA* mutation.

Among the 72 patients with bone-only first metastasis, we detected mutations in three genes, *TP53*, *PIK3CA*, and*AKT*. Our findings with respect to *TP53* and *PIK3CA* mutations agree with previous studies, which have shown that these mutations are the most common mutations not only in primary breast cancer [@B33] but also in metastatic breast cancer [@B18], [@B21]. Although some patients in the previous studies showing *TP53* and *PIK3CA* mutations in metastatic breast cancer were exposed to treatment before tumor specimens were obtained for mutational analysis [@B18], [@B21], the results were the same as in our patients with metastases and untreated primary breast cancer. In our study, the rate of *TP53* mutation tended to be lower in patients with bone-only first metastasis than in those with other-only first metastasis in univariate analysis. However, in multivariate analysis, *TP53* mutation was not significantly associated with site of first metastasis but was associated with hormone-receptor-negative disease. Our results appear to be in agreement with previous reports that *TP53* mutation was associated with breast cancer subtype, especially hormone-receptor-negative disease [@B18], [@B34].

Our study has several limitations. First, we evaluated 46 or 50 genes reported as frequently mutated on the basis of next-generation sequencing. We may have missed some as yet unidentified somatic mutations related to bone-only metastasis. *RUNX2* and *SNAI2*, which may significantly contribute to bone metastasis in breast cancer [@B23]-[@B26], were not evaluated in our current study. Second, the restaging or reimaging strategy was not uniform across patients in the study. We may have missed some cases of bone-only metastasis or other-only metastasis. Third, we could not detect copy number variations or amplifications. Fourth, we were not able to perform subgroup analyses in patients with *AKT1* and*PTEN* mutations because of the small number of patients with these mutations. Finally, this was a retrospective study, and selection bias was unavoidable given the population of patients who were enrolled in the original genomic study. As far as we know, our study is the first study to analyze for somatic mutations associated with bone metastasis in patients with untreated primary breast cancer. Our results may influence future molecular analyses of bone metastasis from breast cancer.

In conclusion, we did not find unique somatic mutations associated with bone-only first metastasis of breast cancer or OS in patients with bone-only first metastasis of breast cancer. The long OS in some patients with breast cancer with bone-only first metastasis may indicate that strategies to target bone metastasis and skeletal-related events would help improve quality of life for these patients. More comprehensive molecular analysis may be needed to further understand the factors associated with bone-only metastatic disease in breast cancer.
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###### 

Demographic and clinical characteristics by site of first metastasis in 389 patients with untreated primary breast cancer with distant metastasis.^a^

                                            \-\-\-\--Value or No. (%) of patients with metastasis\-\-\-\--                             
  ----------------------------------- ----- ---------------------------------------------------------------- ------------ ------------ ---------
  Total (%)                           389   72 (18.5)                                                        94 (24.2)    223 (57.3)   
  Age, years median (range)           389   47 (23-70)                                                       46 (27-72)   48 (25-74)   0.80
  Sex                                                                                                                                  0.70
  Female                              386   72 (100)                                                         93 (99)      221 (99.1)   
  Male                                3     0 (0)                                                            1 (1)        2 (0.9)      
  Race/ethnicity                                                                                                                       0.59
  Black                               36    4 (6)                                                            13 (14)      19 (8.5)     
  Hispanic                            39    9 (12)                                                           7 (7)        23 (10.3)    
  Other                               18    4 (6)                                                            4 (4)        10 (4.5)     
  White                               296   55 (76)                                                          70 (75)      171 (76.7)   
  Menopausal status                                                                                                       0.48         
  Post                                165   33 (46)                                                          35 (37)      97 (43.5)    
  Pre                                 187   36 (50)                                                          50 (53)      101 (45.3)   
  Unknown                             37    3 (4)                                                            9 (10)       25 (11.2)    
  Grade (Nottingham grading system)                                                                          \<0.001                   
  I                                   7     3 (4)                                                            1 (1)        3 (1.3)      
  II                                  128   36 (50)                                                          37 (40)      55 (24.7)    
  III                                 239   31 (43)                                                          54 (57)      154 (69.1)   
  Unknown                             15    2 (3)                                                            2 (2)        11 (4.9)     
  Grade (Nottingham grading system)                                                                          \<0.001                   
  I or II                             135   39 (54)                                                          38 (40)      58 (26.0)    
  III                                 239   31 (43)                                                          54 (58)      154 (69.1)   
  Unknown                             15    2 (3)                                                            2 (2)        11 (4.9)     
  Histology                                                                                                                            0.002
  Ductal                              327   53 (73)                                                          79 (84)      195 (87.4)   
  Lobular                             31    12 (17)                                                          11 (12)      8 (3.6)      
  Other                               31    7 (10)                                                           4 (4)        20 (9.0)     
  IBC                                                                                                                                  0.20
  IBC                                 34    8 (11)                                                           4 (4)        22 (9.9)     
  Non-IBC                             355   64 (89)                                                          90 (96)      201 (90.1)   
  HER2 status                                                                                                                          0.10
  Negative                            354   68 (94)                                                          89 (95)      197 (88.3)   
  Positive                            35    4 (6)                                                            5 (5)        26 (11.7)    
  HR status                                                                                                                            \<0.001
  Negative                            121   9 (12)                                                           22 (23)      90 (40.4)    
  Positive                            268   63 (88)                                                          72 (77)      133 (59.6)   
  TNBC status                                                                                                                          \<0.001
  TNBC                                112   8 (11)                                                           22 (23)      82 (36.8)    
  Non-TNBC                            277   64 (89)                                                          72 (77)      141 (63.2)   
  Subtype                                                                                                                              \<0.001
  HR-/HER2+                           9     1 (2)                                                            0 (0)        8 (3.6)      
  HR+/HER2-                           242   60 (83)                                                          67 (71)      115 (51.5)   
  HR+/HER2+                           26    3 (4)                                                            5 (5)        18 (8.1)     
  TNBC                                112   8 (11)                                                           22 (24)      82 (36.8)    

Abbreviations: HR, hormone receptor; IBC, inflammatory breast cancer; TNBC, triple-negative breast cancer.

^a^Values in table are number of patients (percentage) unless otherwise indicated.

^b^For comparison between patients with bone-only and other-only metastases.

###### 

Overall survival (OS) by site of first metastasis and mutation status.

  Site of first metastasis                        Median OS (95% CI), months   5-year OS rate (95% CI), %   *p* value (unadjusted)^a^
  ----------------------------------------------- ---------------------------- ---------------------------- ---------------------------
  *All patients, regardless of mutation status*                                                             
  All                                             96 (76-119)                  62.2 (57.3-67.6)             
  Bone only                                       126 (87-NR)                  78.2 (68.6-89.0)             0.051
  Bone and other                                  73 (50-117)                  58.0 (48.1-69.9)             
  Other only                                      85 (59-119)                  55.0 (48.1-62.9)             
  *Patients with* TP53*mutation*                                                                            
  Bone only                                       47 (32-NR)                   48.5 (24.8-94.9)             0.487
  Bone and other                                  67 (37-NR)                   52.4 (34.4-79.9)             
  Other only                                      59 (46-130)                  47.3 (33.4-67.0)             
  *Patients with* PIK3CA*mutation*                                                                          
  Bone only                                       98 (72-NR)                   86.7 (71.1-100)              0.679
  Bone and other                                  96 (73-NR)                   80.0 (62.1-100)              
  Other only                                      88 (53-NR)                   57.9 (43.6-76.9)             

Abbreviations: CI, confidence interval; NR, not reached.

^a^For comparison between patients with bone-only and other-only metastases.

###### 

Mutations by site of first metastasis.

                       No. (%) of patients with metastasis                          
  -------------- ----- ------------------------------------- --------- ------------ -------
  All patients   389   72                                    94        223          
  *TP53*                                                                            0.051
  Wild-type      286   61 (85)                               67 (71)   158 (70.9)   
  Mutated        103   11 (15)                               27 (29)   65 (29.1)    
  *PIK3CA*                                                                          0.559
  Wild-type      310   54 (75)                               77 (82)   179 (80.3)   
  Mutated        79    18 (25)                               17 (18)   44 (19.7)    
  *AKT1*                                                                            0.176
  Wild-type      376   70 (97)                               88 (94)   218 (97.8)   
  Mutated        13    2 (3)                                 6 (6)     5 (2.2)      
  *PTEN*                                                                            0.672
  Wild-type      387   72 (100)                              93 (99)   222 (99.6)   
  Mutated        2     0 (0)                                 1 (1)     1 (0.4)      

###### 

Logistic regression analysis of relationship between *TP53* mutation and site of first metastasis and other clinicopathologic characteristics.

  Parameter                                                OR (95% CI)            *p* value (adjusted)
  -------------------------------------------------------- ---------------------- ----------------------
  **Site of first metastasis (other only vs bone only)**   **1.27 (0.61-2.80)**   **0.544**
  Grade (III vs I or II)                                   2.01 (1.12-3.72)       0.022
  HER2 status (positive vs negative)                       0.71 (0.27-1.66)       0.448
  HR status (positive vs negative)                         0.35 (0.21-0.59)       \<0.001
  Histology (lobular vs ductal)                            0.35 (0.05-1.30)       0.174
  Histology (other vs ductal)                              0.60 (0.20-1.53)       0.308

Abbreviations: CI; confidence interval; HR, hormone receptor; OR; odds ratio.
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